
|Videos|May 7, 2015
Mutational Abnormalities in MDS
Author(s)Bart L. Scott, MD
Bart L. Scott, MD, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses breakthrough topics in myelodysplastic syndromes (MDS), such as mutational abnormalities.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
5









































